© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Basel, Switzerland-Novartis Ophthalmics will have exclusive license to develop and market ranibizumab (Lucentis, formerly known as rhuFab V2), an anti-VEGF antibody fragment, outside North America under a new agreement with Genentech Inc.